In order to expand its pipeline beyond the late-stage gastrointestinal drug linaclotide, Ironwood Pharmaceuticals has licensed exclusive global rights to develop and commercialise Bionomics’ Phase I anti‐anxiety compound BNC210 and other related compounds...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: PharmaDeals Ltd